Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $53.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $53.8 million, compared with a TTM value of $53.8 million through Dec 2025, changed N/A, and an annual FY2022 reading of $56.0 million, down 57.45% over the prior year.
  • Non-Current Deffered Revenue was $53.8 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $131.5 million in Q3 2021 and bottomed at $1.1 million in Q1 2023.
  • Average Non-Current Deffered Revenue over 4 years is $75.2 million, with a median of $75.5 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue dropped 10.77% in 2022, then tumbled 98.8% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $106.5 million in 2021, then tumbled by 61.69% to $40.8 million in 2022, then crashed by 97.36% to $1.1 million in 2023, then surged by 4906.98% to $53.8 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ARWR at $53.8 million in Q4 2025, $1.1 million in Q1 2023, and $40.8 million in Q4 2022.